Regeneron Pharmaceuticals (MIL:1REGN) Cyclically Adjusted Book per Share: € (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1REGN Regeneron Pharmaceuticals Inc MIL:1REGN
67 GF Score
Price €688.10
GF Value €798.47
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Cyclically Adjusted Book per Share?

Regeneron Pharmaceuticals MIL:1REGN 67 Cyclically Adjusted Book per Share is € as of Jun. 2026. GuruFocus rates MIL:1REGN with a GF Score™ of 67/100 and a GF Value™ of €798.47 (Modestly Undervalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted book value per share for the three months ended in Jun. 2026 was €268.247. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is for the trailing ten years ended in Jun. 2026.

During the past 12 months, Regeneron Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 20.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 23.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 28.80% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 31.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Regeneron Pharmaceuticals was 35.90% per year. The lowest was -4.00% per year. And the median was 16.15% per year.

As of today (2026-09-22), Regeneron Pharmaceuticals's current stock price is €688.10. Regeneron Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was . Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Regeneron Pharmaceuticals was 32.09. The lowest was 3.43. And the median was 9.82.


Regeneron Pharmaceuticals  (MIL:1REGN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Regeneron Pharmaceuticals was 32.09. The lowest was 3.43. And the median was 9.82.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Regeneron Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Regeneron Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Cyclically Adjusted Book per Share Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regeneron Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MIL:1REGN vs MRNA, RVMD, ONC: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


MIL:1REGN
67GF Score
Regeneron Pharmaceuticals Inc MIL:1REGN
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regeneron Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=268.247/333.9520*333.9520
=268.247

Current CPI (Jun. 2026) = 333.9520.

Regeneron Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201609 37.895 241.428 52.418
201612 39.792 241.432 55.041
201703 42.814 243.801 58.645
201706 45.186 244.955 61.603
201709 47.661 246.819 64.486
201712 47.542 246.524 64.402
201803 49.514 249.554 66.259
201806 57.015 251.989 75.560
201809 62.603 252.439 82.818
201812 70.277 251.233 93.416
201903 76.758 254.202 100.839
201906 78.034 256.143 101.739
201909 87.816 256.759 114.217
201912 89.588 256.974 116.425
202003 98.561 258.115 127.519
202006 76.058 257.797 98.526
202009 80.983 260.280 103.905
202012 84.253 260.474 108.020
202103 95.557 264.877 120.476
202106 119.528 271.696 146.916
202109 137.211 274.310 167.044
202112 151.870 278.802 181.912
202203 163.446 287.504 189.852
202206 180.716 296.311 203.673
202209 201.141 296.808 226.313
202212 193.758 296.797 218.014
202303 197.135 301.836 218.111
202306 202.154 305.109 221.264
202309 216.199 307.789 234.577
202312 214.922 306.746 233.984
202403 226.785 312.332 242.483
202406 238.816 314.175 253.849
202409 238.660 315.301 252.777
202412 258.643 315.605 273.679
202503 251.439 319.799 262.567
202506 239.707 322.561 248.172
202509 250.210 324.800 257.260
202512 251.789 324.054 259.480
202603 259.740 330.213 262.681
202606 268.247 333.952 268.247

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of € mean?
Regeneron Pharmaceuticals (MIL:1REGN) has a Cyclically Adjusted Book per Share of € as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Regeneron Pharmaceuticals' current Cyclically Adjusted Book per Share is €. Overall, Regeneron Pharmaceuticals has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Cyclically Adjusted Book per Share compare to MRNA and RVMD?
Regeneron Pharmaceuticals' Cyclically Adjusted Book per Share of € can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Cyclically Adjusted Book per Share is €. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (MIL:1REGN) is currently considered Modestly Undervalued. The stock's GF Value™ is €798.47, compared to a current price of €688.10 — trading 13.8% below its estimated fair value. The current Cyclically Adjusted Book per Share is €. Regeneron Pharmaceuticals' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Regeneron Pharmaceuticals (MIL:1REGN), the current Cyclically Adjusted Book per Share is € as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (MIL:1REGN) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of €688.10 is trading 13.8% below its estimated GF Value™ of €798.47. GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MIL:1REGN:

  • Cyclically Adjusted Book per Share:
  • GF Value™: €798.47 vs. price of €688.10 (13.8% below fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the MIL:1REGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
67GF Score

Get the complete analysis for MIL:1REGN

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€688.10
Price
€798.47
GF Value